The stock of Burning Rock Biotech (BNR, Financial) has experienced a significant price increase of 7.64%. The current trading price is $3.24 per share, with a trading volume of 8,477 shares and a turnover rate of 0.08%. The stock's price fluctuation stands at 6.31%.
According to recent financial reports, Burning Rock Biotech reported a revenue of $18.71 million, a net loss of $14.92 million, and an earnings per share (EPS) of -$1.45. The company's gross profit was $13.18 million with a price-to-earnings (P/E) ratio of -0.42. As of now, no institutional ratings such as "buy," "hold," or "sell" have been issued for the stock.
In the life sciences sector where Burning Rock Biotech operates, the overall market increase is 0.09%. Notable performers in the sector include Inotiv, Inc., Charles River Laboratories, and Medpace Holdings, Inc. with significant gains. Actively traded stocks include Endra Life Sciences Inc., Ispecimen Inc., and Precision Science, with turnover rates of 28.88%, 8.91%, and 6.85% respectively. Stocks with substantial price volatility include Endra Life Sciences Inc., Inotiv, Inc., and T2 Biosystems, Inc., with amplitude fluctuations of 32.67%, 29.92%, and 19.84% respectively.
Burning Rock Biotech specializes in cancer diagnostics, offering Next-Generation Sequencing (NGS)-based cancer therapy selection. Its platform is grounded in proprietary technology, a comprehensive product lineup, and a market-driven infrastructure. The company's operations are divided into central laboratory services, in-hospital services, and pharmaceutical research and development, with the central lab services contributing the majority of its revenue. Key products include Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus.
